Overview

Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)

Status:
Completed

Trial end date:
2006-01-01

Target enrollment:

Participant gender:

Summary

The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety. Ciclesonide will be inhaled at one dose level once daily, using an inhaler device with or without spacer. The study duration consists of a baseline period (1 to 3 weeks) and a treatment period (12 weeks).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ciclesonide